The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
about
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's diseaseDHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet?Acetylcholinesterase inhibitors: pharmacology and toxicology.Cattle encephalon glycoside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitarget anti-Alzheimer's drug candidatesOrganic carbamates in drug design and medicinal chemistryEfficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in ratsSchizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ1-42-induced memory impairment in micePharmacist-based Donepezil Outpatient Consultation Service to improve medication persistenceBerberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in RatsSynthesis and in silico evaluation of 1N-methyl-1S-methyl-2-nitroethylene (NMSM) derivatives against Alzheimer disease: to understand their interacting mechanism with acetylcholinesterase.Responsiveness to nicotine of neurons of the caudal nucleus of the solitary tract correlates with the neuronal projection target.Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Disease-modifying drugs in Alzheimer's disease.Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.Current advances in transdermal delivery of drugs for Alzheimer's disease.Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin.Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure-Activity Relationship.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
P2860
Q33911859-FE2F9584-3534-4CFE-9009-D6429C35F256Q34023271-2820A204-E1A1-47D5-AA7D-983489D8A3DDQ34381860-BD0DAC6D-88B0-4F2E-86FA-2632C5B5CA2CQ35167977-2D673E81-CD9E-4BF7-A40E-E562E5B342A4Q35365543-D93E4D4D-EFBD-44E0-BA89-F21FC8A7B3F3Q35539649-70FBBFDF-3586-4372-B33A-F11243240076Q35545032-35499B22-A45F-4570-9614-0A07FB38C194Q36102657-4A8E0BB8-477D-4802-9534-E3823A0ED6E1Q36222012-98207484-72C3-46C1-BA25-77BB50035BA8Q36241424-97651453-0D47-432D-9AB4-017AC8FF291CQ36288118-8757EB4D-6632-42FF-A829-6FD600F1D2F7Q36532483-7A544034-1845-47A9-8D12-3C4834A3A7EBQ36678091-F14113E3-6A95-4804-9315-37DAB7B55683Q37385577-668A6E92-9AA4-4B38-B593-6FB69A879753Q37390739-63D08AE1-C52B-484B-8435-F89FD1912122Q37405505-88D2AEF6-CE37-4660-994D-2ED04ABC55EAQ38221488-5ACA868B-018B-4BA6-81F4-31E92C4CC278Q38350602-9FCC8054-4B06-48A5-9D53-1FEBE3F770F5Q38657942-54BA75AE-9B53-4BD5-B633-EA73DF234FB7Q42113984-FF0D1759-3319-4C29-BCF1-EA6635F67C3DQ42365798-82533A30-55E1-4565-B6D8-83389330F27EQ49703452-ABBDE69C-C5CE-4FE1-9E96-FE86EC15B924Q50328399-24F57A09-A8C3-4CFD-B111-5E14BD1F7786Q58794595-12CD4A43-BB97-42C3-8D32-958845A52BFD
P2860
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@ast
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@en
type
label
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@ast
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@en
prefLabel
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@ast
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@en
P1476
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
@en
P2093
P577
2002-06-01T00:00:00Z